clinical trial · NCT04729517
Efficacy and Safety Study of AI201901 in Allergic Rhinitis Patients
Abdi Ibrahim Ilac San. ve Tic A.S.·phase3·completed·n = 210
Allergic Rhinitis Due to AllergensAI201901Azelastine Hydrochloride
brief summary
This is a prospective, national, randomized, multicenter, parallel group, Phase III study that evaluates the effects of AI201901 in Allergic Rhinitis patients, where they will spray twice a day against azelastine into both nostrils during a 28-day follow-up period.
started
Apr 20, 2021
primary completion
Mar 3, 2023
completion
May 2, 2023
last updated
Sep 8, 2023
official title
Randomized Multicenter Phase III Efficacy and Safety Study of AI201901 in Allergic Rhinitis Patients (HILARIA)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol